Cyclin-Dependent Kinase (CDK) Inhibitors Therapeutics Pipeline Projects Vast Growth Ahead     |    CAD Software Market to Reach $11,097 Million by 2023     |    Friedreich’s Ataxia (FRDA) Therapeutics Pipeline to Receive Various Drug Designations from the USFDA and EMA in the Coming Years
P&S Market Research - A market research firm

Autoimmune Treatment Market

P&S Market Research-Autoimmune Treatment Market report

Global Autoimmune Treatment Market Size, Share, Development, Growth and Demand Forecast to 2023

Delivery : 24-72 Working Hours
Report Code: LS10376
Available Format: pdf

The global autoimmune treatment market is growing significantly due to increasing incidences of autoimmune diseases, up surging healthcare expenditure, and advancements in the technologies for the development of autoimmune diseases therapeutics. Autoimmune diseases are chronic in nature and do not have permanent treatment. This creates ample growth opportunity for the autoimmune treatment market, to grow at a considerable rate in the coming years. The advanced research and development facilities, and new product developments by the companies are propelling the demand for cost effective treatment of autoimmune diseases.

The abnormal response of immune system leads to autoimmune disorders. Normally, the body’s immune system provides protection against foreign bodies or harmful substances. However, in the autoimmune disorders, the immune system fails to differentiate between a healthy tissue or cell and a harmful substance (antigen), and destroys the normal tissues. Autoimmune diseases have high prevalence among female children and women. There are more than 80 prevailing autoimmune diseases. Some of the most common autoimmune disorders include psoriasis, multiple sclerosis, rheumatoid arthritis, type 1 diabetes, systemic lupus erythematosus, inflammatory bowel disease, and Addison’s disease.

Based on applications, the autoimmune treatment market can be categorized as type 1 diabetes, inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, psoriasis, rheumatoid arthritis, thyroid disease, and others. Rheumatoid arthritis leads the global autoimmune treatment market, due to high prevalence of rheumatoid arthritis worldwide.

Based on technology, the autoimmune treatment market is segmented as bridge therapy, phototherapy, topical therapy, fecal bacteriotherapy, recombinant technology, diseases-modifying antirheumatic drugs, helminthic therapy, and hematopoietic stem cell transplantation. And based on product types, the autoimmune treatment market can be categorized as diagnostic equipment, drugs, therapeutic equipment, and other products. The drugs category leads the global autoimmune treatment market, in terms of revenue. Drugs are further classified as methotrexate, non-steroidal anti-inflammatory drugs, corticosteroids, glucocorticoids, 5-aminosalicylic acid, and others.

Some of the factors driving the growth of the autoimmune treatment market are aging population, high incidences of autoimmune diseases, and increasing healthcare expenditure. In addition, the major pharmaceutical companies are investing huge amount in the R&D of drugs for the treatment of autoimmune diseases, which in turn is driving the growth of the global autoimmune treatment market. However, the high cost and side effect associated with drugs, lack of standardized treatment procedure, and low insurance coverage for autoimmune diseases are some of the factors restraining the growth of the global autoimmune treatment market to some extent.

Geographically, North America leads the global autoimmune treatment market, due to aging population, high incidences of autoimmune diseases, increased healthcare expenditure, and excessive R&D investment for the development of drugs for autoimmune diseases. Asia-Pacific is the fastest growing region in the global autoimmune treatment market. The major reasons for the fastest growth in the region are increasing healthcare expenditure and improving healthcare infrastructure. Moreover, the autoimmune treatment market is growing, due to increasing disposable income and large population suffering from autoimmune diseases in the emerging countries, such as India and China.

Some of the major players operating in the global autoimmune treatment market are Abott, Bristol-Myers Squibb Company, Amgen Inc., Pfizer Inc., Bayer AG, F. Hoffmann-La Roche AG, Eli Lilly and Company, Novartis AG, Johnson & Johnson Services Inc., Merck & Co. Inc., Sanofi, GlaxoSmithKline PLC, Biogen, Boehringer Ingelheim GmbH, AstraZeneca PLC, and Astellas Pharma Inc.


Report Coverage

  • Provides comprehensive understanding of the market with the help of informed market outlook, opportunities, challenges, trends, size and growth, competitive analysis, major competitors and Porter analysis
  • Identifies the key drivers of growth and challenges of the key industry players. Also, assesses the future impact of the propellants and restraints on the market
  • Uncovers potential demands in the market
  • Porter analysis identifies competitive forces within the market
  • Provides information on the historical and current market size and the future potential of the market
  • Provides sizes of key regional markets using yardsticks of segments
  • Highlights the competitive scenario of the market and major competitors
  • Provides profiles of major competitors of the market including details of their operations, product and services, recent developments and key financial metrics. Profiles provide better understanding of competition as well as the demands of the market.

Place An Order

Single User License

Single User License authorizes access of the publication to single user, i.e. the buyer of the report.

Group License

Group License authorizes access of the publication upto 5 users.

Enterprise License

Enterprise License provides right to distribute copies of the publication across the organization and its subsidiaries.


Pre-Purchase Enquiry

Contact Us

  • U.S. Center : 347 5th Ave. #1402- 210 New York City, NY 10016 United States
  • Asian Center : B-28, Sector 1, Noida, U.P. - 201301 India.

Secure Online Payments

  • Payment